Clinical trials recruiting in Auckland, New Zealand

Phase breakdown

Conditions recruiting in Auckland, New Zealand

Recruiting trials in Auckland, New Zealand

• A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  NCT06863272 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
  NCT06961006 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
  NCT06937203 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
  NCT06700538 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)
  NCT07564154 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
  NCT06747949 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
  NCT07235384 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
  NCT06427941 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B
  NCT07200193 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female)
• A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
  NCT07230353 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
  NCT07491172 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
  NCT05646862 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
  NCT06345729 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
  NCT06077760 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
  NCT07241390 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female)
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  NCT06312176 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
  NCT06671483 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B
  NCT07389044 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
  NCT06312137 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
  NCT06929273 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
  NCT06625060 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
  NCT07037901 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
  NCT06951698 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
  NCT07481981 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
  NCT06647069 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
  NCT07282574 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
  NCT06878261 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
  NCT06629779 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
  NCT07662122 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
  NCT07754461 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
  NCT05613023 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
  NCT07365332 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
  NCT07222267 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Assessment of Breathing Pattern During NIV
  NCT06682286 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults
  NCT04608630 · Phase: Phase 2 · Ages: 50 Years and older · Sex: All (male and female)
• Calibr-Ì: Comparative Evaluation of Phantomless Calibration Methods to Quantify Bone Mineral Density for Opportunistic Analysis of CT Scans
  NCT06454617 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
  NCT06961214 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation
  NCT07462910 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
  NCT07284901 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
  NCT07284875 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
  NCT05714085 · Phase: Phase 2, Phase 3 · Ages: 29 Days to 17 Years · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• IKS014 in Advanced Solid Tumors That Express HER2
  NCT05872295 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial
  NCT05072314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
  NCT03860883 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Neoadjuvant Darovasertib in Primary Uveal Melanoma
  NCT07015190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation
  NCT07436299 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
  NCT06680232 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis
  NCT06934252 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B
  NCT06671093 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
  NCT03573089 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
  NCT04895839 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male
• PulseSelect™ PFA Global Registry
  NCT06393920 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
  NCT07413939 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
  NCT06697301 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
  NCT06850727 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Study to Evaluate the Safety and Effectiveness of the REAL INTELLIGENCE™ CORI™ in Total Knee Arthroplasty (TKA) Procedure
  NCT04848896 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
  NCT06353386 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
  NCT06058585 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• The EXCEL Registry of Patients Requiring ECMO
  NCT03793257 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study
  NCT04204915 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Zenith LAA Occlusion System
  NCT05951101 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
  NCT07181109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Auckland, New Zealand?

72 recruiting trials have at least one study site in Auckland, New Zealand.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.